** Shares of Telix Pharmaceuticals TLX.AX rise as much as 3.2% to a record high of A$29.610; last up 2.6%
** The biopharma co says it does not expect business to be affected by the current international trade tariffs levied by the U.S. Government
** Co currently generates most of its revenue from U.S. sales of Illuccix, its prostrate cancer diagnostic drug
** Stock climbed 19.2% in January
(Reporting by Manasi Dasa Sundeep in Bengaluru)
((Manasi.DasaSundeep@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。